New EU Fee Regulation: Smaller Firms & Orphan Drugs Will Still Benefit From Full Reductions

While annual fees for marketing authorization applications and annual payments to the European Medicines Agency are set to increase from 2025, micro-sized companies and SMEs that make orphan drugs will still benefit from full reductions.